Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000919574-25-004851
Filing Date
2025-08-14
Accepted
2025-08-14 13:32:57
Documents
3

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 8650
2 d11862592_ex99-a.htm EX-99 8091
3 d11862592_ex99-b.htm EX-99 846
  Complete submission text file 0000919574-25-004851.txt   19267
Mailing Address 500 PARK AVENUE 2ND FLOOR NEW YORK NY 10022
Business Address 500 PARK AVENUE 2ND FLOOR NEW YORK NY 10022 212-848-0519
SAMLYN CAPITAL, LLC (Filed by) CIK: 0001421097 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE
Type: SCHEDULE 13G/A

Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Subject) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89443 | Film No.: 251217047
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)